초록 ▼

A new particle morphology of glucocorticosteroids is described. The forms have a particle morphology that is particularly well suited for use in an inhaled corticosteroid drug suspension formulation for delivery from a next generation nebulizer device. Use of the new glucocorticosteroid particles en

A new particle morphology of glucocorticosteroids is described. The forms have a particle morphology that is particularly well suited for use in an inhaled corticosteroid drug suspension formulation for delivery from a next generation nebulizer device. Use of the new glucocorticosteroid particles enables enhanced drug delivery efficiency and increased residence time of the delivered drug in the lungs. New methods for producing glucocorticosteroid particles having these specific particle morphologies are also described. The methods provide a simplified, reproducible and scalable particle formation process that can produce glucocorticosteroid particles having a narrow particle size and shape distribution, a low surface energy, a low aspect ratio, uniform particle morphology and a reduced specific surface area.

대표청구항 ▼

1. A method for forming a particulate budesonide composition, said method comprising: (a) dissolving budesonide in a solvent comprising a mixture of water-miscible solvent and a partially water-miscible solvent to form a solution;(b) combining the solution with an antisolvent containing a dispersion

1. A method for forming a particulate budesonide composition, said method comprising: (a) dissolving budesonide in a solvent comprising a mixture of water-miscible solvent and a partially water-miscible solvent to form a solution;(b) combining the solution with an antisolvent containing a dispersion enhancer with agitation to produce particles of budesonide, wherein the particles of budesonide have a particle size distribution with mean diameter of from 1 to 10 microns, a specific surface area of from 1 to 3 m2/g, and have a square bifrustum shape, with a mean largest dimension of less than 4 microns and a mean aspect ratio of less than 2.0. 2. The method of claim 1, wherein the particles have a mean diameter of from 1 to 3 microns. 3. The method of claim 1, wherein the particles have a specific surface area of from 2 to 3 m2/g. 4. The method of claim 1, wherein the partially water-miscible solvent is selected from the group consisting of ethyl acetate, isopropyl acetate, diethyl ether, dichloromethane, methyl ethyl ketone, and methyl isobutyl ketone, or mixtures thereof. 5. The method of claim 4, wherein the partially water-miscible solvent is ethyl acetate. 6. The method of claim 1, wherein the water-miscible solvent is selected from the group consisting of acetone, acetonitrile, methanol, ethanol, isopropanol, dimethyl sulfoxide, or mixtures thereof. 7. The method of claim 6, wherein the water-miscible solvent is methanol. 8. The method of claim 1, wherein the water-miscible solvent comprises from 10 to 90% by volume of the solution. 9. The method of claim 8 wherein the water-miscible solvent is methanol and the partially-water miscible solvent is ethyl acetate. 10. The method of claim 9, wherein the solution comprises 50% by volume of methanol and 50% by volume of ethyl acetate. 11. The method of claim 1, wherein the antisolvent is water. 12. The method of claim 1 wherein the majority of the particles have a square bifrustum shape. 13. The method of claim 1, wherein the antisolvent contains 0.01 to 5 wt % of the dispersion enhancer. 14. The method of claim 13, wherein the dispersion enhancer is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polyethylene glycol, poloxamer, or mixtures thereof. 15. The method of claim 14, wherein the dispersion enhancer is polysorbate 80. 16. The method of claim 14, wherein the antisolvent contains about 0.05 w/v % polysorbate 80. 17. The method of claim 1, wherein agitation in step (b) is carried out under conditions of high shear or high pressure. 18. The method of claim 17, wherein agitation in step (b) is carried out using a rotor-stator or a high-pressure homogenizer apparatus. 19. The method of claim 1, wherein the antisolvent is at a temperature of from −10 to 50° C. when combined with the solution in step (b). 20. The method of claim 19, wherein the antisolvent is about 5° C. when combined with the solution in step (b). 21. The method of claim 1, wherein the antisolvent further contains one or more excipients selected from the group consisting of buffering agents, an isotonicity agent and an antioxidant. 22. The method of claim 1 further comprising one or more steps selected from the group consisting of sterile filtration of the solution and sterile filtration of the antisolvent. 23. Budesonide particles comprising: crystalline particles of budesonide having a particle size distribution with mean diameter of 1 micron to 10 microns;the particles further having a specific surface area of between 1 m2/g and 3 m2/g; and the particles have a square bifrustum morphology with a mean largest dimension of less than 4 microns and a mean aspect ratio of less than 2.0. 24. The budesonide particles of claim 23, wherein the particles of budesonide have a mean diameter of 1 micron to 3 microns. 25. The budesonide particles of claim 23, wherein the square bifrustum-shaped particles have a specific surface area of between 2 m2/g and 3 m2/g. 26. The budesonide particles of claim 23 wherein said particles exhibit an in-vitro dissolution rate of less than 90% of cumulative release after 1 minute when measured in a USP dissolution apparatus II, in 500 ml of simulated epithelial lung fluid at 37° C. and 75 rpm stirring rate, under sink conditions.